title: 'On-demand' romiplostim therapy in immune thrombocytopenia.
abstract: OBJECTIVE
  Although thrombopoietin receptor agonists are a second-line treatment for refractory immune thrombocytopenia (ITP), we lack guidelines recommending maintenance modality in patients who achieve complete remission (CR).
  
  
  METHODS
  We report a patient with refractory ITP who achieved CR on romiplostim. Obtaining romiplostim for 6 months of therapy, we decided to try extending this by modifying the standard treatment regimen. Romiplostim was successfully administered 'on-demand', only if the patient's platelet count dropped below 150 × 109/L, over a period of 12 months.
  
  
  CONCLUSIONS
  The strategy of 'on-demand' therapy is a promising procedure for the maintenance of response, lowering costs and improving treatment safety.
authors: Clinic of Haematology, Clinical Centre of Serbia, Belgrade, Serbia.|Faculty of Medicine, University of Belgrade, Belgrade, Serbia.
authors: M
authors: M
authors: Mitrovic
authors: Clinic of Haematology, Clinical Centre of Serbia, Belgrade, Serbia.|Faculty of Medicine, University of Belgrade, Belgrade, Serbia.
authors: I
authors: I
authors: Elezovic
authors: Clinic of Haematology, Clinical Centre of Serbia, Belgrade, Serbia.|Faculty of Medicine, University of Belgrade, Belgrade, Serbia.
authors: N
authors: N
authors: Suvajdzic-Vukovic
keywords: immune thrombocytopenia; thrombopoietin receptor agonists; ‘on-demand’ therapy